Previous 10 | Next 10 |
Summary Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront and up to $1.1 billion in milestones. The $937 million agreement between Beijing InnoCare and Biog...
Summary TG Therapeutics is a biopharmaceutical company focused on developing innovative treatments for B-cell malignancies and autoimmune diseases. Briumvi (ublituximab) is the company's lead product, an FDA-approved monoclonal antibody indicated for the treatment of relapsing forms of ...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
Summary Mereo and Ultragenyx are collaborating to develop setrusumab, a sclerostin inhibitor, for treating patients with Osteogenesis Imperfecta. ASTEROID Phase 2 trial showed that setrusumab improved bone markers and density, and strength but not patient-reported outcomes or fracture r...
Novartis' ( NYSE: NVS ) board appointed Gilbert Ghostine as chairman-designate of the new board of Sandoz. Ghostine has served as CEO of Geneva-based privately owned perfume and taste company Firmenich since 2014. Ghostine will take up the role after the spin-off of Sandoz fr...
Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...
Summary This article is the first of a 3-part series discussing 10 sectors that could provide high returns in the future. This first part covers Artificial Intelligence (AI) and Healthcare Technology, highlighting companies and potential growth opportunities. We discuss why you shou...
Summary Readers will be updated on previous articles where I discuss the issues MannKind faces with their business model. I will discuss their planned development of clofazimine and the issues they face. I will discuss the need for MannKind to adopt a new business model. " K...
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Summary Novo Nordisk is a market leader and the only pure-play in the diabetes and obesity care space. The nature of the diabetes care business makes Novo Nordisk rather recession-proof. The stock priced in much of the assumed future growth and I have concerns about competition, esp...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...